Uniprim Powder

Trimethoprim/sulfadiazine is indicated in horses where potent systemic antibacterial action against sensitive organisms is required.  Trimethoprim/sulfadiazine is indicated where control of bacterial infections is required during treatment of:

Trimethoprim/sulfadiazine should not be used in horses showing marked liver parenchymal damage, blood dyscrasias, or in those with history of sulfonamide sensitivity.

Do not use in horses intended for human consumption.

Toxicity is low.  The acute toxicity of trimethoprim/sulfadiazine is more than 5 g/kg orally in rats and mice.  No significant changes were recorded in rats given doses of 600 mg/kg per day for 90 days.

Horses treated intravenously with trimethoprim/sulfadiazine 48% injection have tolerated up to five times the recommended daily dose for 21 consecutive days without clinical effects or histopathological changes.

Lengthening of clotting time was seen in some of the horses on high or prolonged dosing in one of two trials.  The effect, which may have been related to a resolving infection, was not seen in a second similar trial.

Slight to moderate reductions in hematopoietic activity following high, prolonged dosage in several species have been recorded.  This is usually reversible by folinic acid (leucovorin) administration or by stopping the drug.  During long-term treatment of horses, periodic platelet counts and white and red blood cell counts are advisable.

The effect of trimethoprim/sulfadiazine on pregnancy has not been determined.  Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of trimethoprim/sulfadiazine.

The recommended dose is 3.75 g trimethoprim/sulfadiazine per 110 lbs (50 kg) body weight per day.  Administer trimethoprim/sulfadiazine Powder orally once a day in a small amount of palatable feed.

The usual course of treatment is a single, daily dose for five to seven days.

Continue acute infection therapy for two or three days after clinical signs have subsided.

If no improvement of acute infections is seen in three to five days, re-evaluate diagnosis.

Trimethoprim/sulfadiazine may be used alone or in conjunction with intravenous dosing.  Following treatment with trimethoprim/sulfadiazine 48% injection, therapy can be maintained using oral powder.

A complete blood count should be done periodically in patients receiving trimethoprim/sulfadiazine for prolonged periods.  If significant reduction in the count of any formed blood element is noted, treatment with trimethoprim/sulfadiazine should be discontinued.